We narrowed to 7,820 results for: 11

#55641-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Sept. 27, 2023

Academic Institutions and Nonprofits only

#59170-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 7, 2018

Academic Institutions and Nonprofits only

#55641-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 25, 2021

Academic Institutions and Nonprofits only

#55641-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Oct. 21, 2024

Academic Institutions and Nonprofits only

#106180-AAV5

Ready-to-use AAV5 particles produced from pAAV.hSynap-FLEX.SF-iGluSnFR.A184S (#106180). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-iGluSnFR.A184S plasmid DNA. Synapsin-driven, Cre-dependent expression of glutamate sensor iGluSnFR (high affinity). These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

March 19, 2021

Academic Institutions and Nonprofits only

#59170-AAV5

Ready-to-use AAV5 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

July 21, 2017

Academic Institutions and Nonprofits only

#55634-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. EF1a-driven mCherry and bicistronic Flp recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

May 31, 2019

Academic Institutions and Nonprofits only

#106174-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 14, 2024

Academic Institutions and Nonprofits only

#106183-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.A184S (#106183). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.A184S plasmid DNA. Synapsin-driven, Cre-dependent SF-Venus-iGluSnFR.A184S glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Dec. 26, 2018

Academic Institutions and Nonprofits only

#62726-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-Chronos-tdTomato (#62726). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-tdTomato plasmid DNA. Syn-driven Chronos-tdTomato expression for optogenetic neuronal activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 7, 2018

Academic Institutions and Nonprofits only

#140555-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA-mut (#140555). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA-mut plasmid DNA. Synapsin-driven expression of control dopamine sensor GRAB_DA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#122100-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-GFP (#122100). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-GFP plasmid DNA. EF1a-driven expression of GFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#55638-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#106181-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynap-FLEX.SF-iGluSnFR.A184V (#106181). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-iGluSnFR.A184V plasmid DNA. Synapsin-driven, Cre-dependent expression of glutamate sensor iGluSnFR (medium affinity). These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

March 19, 2021

Academic Institutions and Nonprofits only

#106185-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.S72A (#106185). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.S72A plasmid DNA. Synapsin-driven, Cre-dependent SF-Venus-iGluSnFR.S72A glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Dec. 26, 2018

Academic Institutions and Nonprofits only

#61151

DH10B modified to constitutively express araC, lacI, and tetR, integrated at the attB site on the E Coli genome. This is DH10B-ALT-Tet with the tetracycline resistance cassette deleted.

Matthew Bennett

Shis et al Proc Natl Acad Sci U S A. 2013 Mar 26;11

Oct. 2, 2015

Academic Institutions and Nonprofits only